New vaccination lowers pneumonia incidence among elderly people

Researchers at University Medical Center (UMC) of Utrecht have discovered a vaccine that lowers incidents of pneumonia among elderly people.

The research, carried out among 85,000 Dutch subjects over the age of 65, the research reveals that vaccination halves the number of hospitalisations.

The ‘Community-acquired pneumonia immunization Trial in Adults’ – CAPiTA – studied the effect of vaccine PCV13, which targets 13 strains of Streptococcus pneumoniae, the main cause of pneumonia.

“It has now been demonstrated for the first time that a vaccine can prevent pneumonia in elderly people”, said Marc Bonten, professor of Molecular Epidemiology of Infectious Diseases at the UMC Utrecht and research leader of the CAPiTA study.

“The vaccine offers long-term protection: its effectiveness did not decrease in the four years of the study. If all people over the age of 65 were to be given PCV13, this would result in several hundred fewer hospitalizations in the Netherlands.”

UMC Utrecht carried out the research study in collaboration with Pfizer.


[ Readmore. ]
This site uses cookies. Find out more about this site’s cookies.